Google partnent company Alphabet and UK farmaceutical company GlaxoSmithKline (GSK) are joining in a joint ventrue to invest 715 million US dollars in bioelectronics according to Reuters.
GSK is participating for 55% and the Verili Life Sciences on behalf of Alphabet gets 45%. The total investments are spread over seven years. The new Galvani Bioelectronics is planning to develop medical treatments using a small implant that stimulates physical reactions in the body with electrical impulses. These methods are according to Galvani going to help treat chronic diseases like; asthma, diabetes and arthritis.